Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Broad based buying in markets
Fri, 21 Feb 11:30 am

After opening firm, the Indian indices are trading well above the dotted line in the morning session. All sectoral indices are trading in the green. The buying interest is the highest in banking and FMCG stocks.

The BSE-Sensex is trading up 175 points and the NSE-Nifty is trading up 55 points. The BSE Mid Cap index is trading up 0.6% and the BSE Small Cap index is trading up 0.7%. The rupee is trading at 62.15 to the US dollar.

Telecom stocks are trading mixed today. While Tata Teleservices and Mahanagar Telephone Nigam Limited (MTNL) are leading the gainers, Bharti Airtel and Reliance Communications are leading the losers. India's largest telecom service provider, Bharti Airtel, is facing legal troubles in Africa. Its subsidiary in the country of Nigeria has lost a long standing case to Econet Wireless Nigeria (EWN). The case relates to the shareholding of the company. A Nigerian court has upheld EWN's claim that it holds 5% stake in the firm and Airtel has been ordered to pay it a compensation of about US$ 3 bn. Bharti has challenged the order in the Supreme Court of Nigeria. Bharti Airtel holds 79.06% stake in Airtel Nigeria. Nigeria is the largest market for Airtel in Africa as it contributes about 30% of revenues from the continent. Bharti Airtel is trading down 0.8% today.

Indian pharma stocks are trading mixed today. While Panacea Biotech and Ranbaxy are trading lower, Natco Pharma and Dishman Pharma are trading higher. Sun Pharma has announced its 3QFY14 results. The company has reported 51% YoY growth in sales led by growth in domestic and international formulation business. Its US generics business did well which grew by 79% YoY during the quarter. The company continued to benefit from drugs such as Doxil where it is the sole supplier in the US in light of the problems that the innovator Johnson & Johnson is facing. Its operating margins improved by 1.9% to 46.4% for the quarter largely on account of reduction in raw material and staff costs (as percentage of sales). Strong growth in operating profits and higher other income along with miniscule growth in tax expenses, led to healthy growth in bottomline by 74% YoY.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Broad based buying in markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.